Eukaryotic Translation Initiation Factor 3a (eIF3a) Promotes Cell Proliferation and Motility in Pancreatic Cancer

Shu-qian Wang,1 Yu Liu,1 Min-ya Yao,1 and Jing Jin2

1General Surgery Department, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China; 2Department of Neurosurgery, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China

Received: 6 March 2016 Accepted: 27 June 2016

Address for Correspondence: Jing Jin, MM Department of Neurosurgery, The First Affiliated Hospital, College of Medicine, Zhejiang University, No. 79, Qingchun road, Hangzhou 310003, Zhejiang, China E-mail: hughjin@126.com

INTRODUCTION

Pancreatic cancer is one of the leading causes of cancer death, with a 5-year survival rate of < 5% (1,2). Less than 20% of patients present with potentially resectable pancreatic cancer, whereas the remaining patients have locally advanced, unresectable, or metastatic disease (3). The disease is characterized by rapid tumor spread and dismal prognosis. Moreover, most patients are diagnosed at an advanced stage and are not candidates for local treatments, such as surgical resection and irradiation (4). Therefore, identifying additional target molecules that are crucially involved in the growth of pancreatic cancer cell growth is necessary in developing an effective treatment.

Plenty of eukaryotic initiation factors (eIFs) are involved in translation initiation, which is the significant rate-limiting step in the process of protein translation (5). Among all eIFs, eIF3 is the largest family member and contains at least 13 subunits, consecutively designated eIF3a to eIF3m (6,7). The eIF3 family members are demonstrated to play two important roles in protein translation. On one hand, eIF3 can bind onto the 40S ribosome and promote loading of the ternary complex of Met-tRNA/ eIF2-GTP, finally forming the 43S preinitiation complex. On the other hand, eIF3 notably assists eIF4 to recruit mRNAs to the 43S complex (8-10). The above observations suggest that eIF3 is one of the most important initiation factors in eukaryote.

Identifying a target molecule that is crucially involved in pancreatic tumor growth and metastasis is necessary in developing an effective treatment. The study aimed to investigate the role of the eukaryotic translation initiation factor 3a (eIF3a) in the cell proliferation and motility in pancreatic cancer. Our data showed that the expression of eIF3a was upregulated in pancreatic ductal adenocarcinoma as compared with its expression in normal pancreatic tissues. Knockdown of eIF3a by a specific shRNA caused significant decreases in cell proliferation and clonogenic abilities in pancreatic cancer SW1990 and Capan-1 cells. Consistently, the pancreatic cancer cell growth rates were also impaired in xenotransplanted mice. Moreover, wound-healing assay showed that depletion of eIF3a significantly slowed down the wound recovery processes in SW1990 and Capan-1 cells. Transwell migration and invasion assays further showed that cell migration and invasion abilities were significantly inhibited by knockdown of eIF3a in SW1990 and Capan-1 cells. Statistical analysis of eIF3a expression in 140 cases of pancreatic ductal adenocarcinoma samples revealed that eIF3a expression was significantly associated with tumor metastasis and TNM staging. These analyses suggest that eIF3a contributes to cell proliferation and motility in pancreatic ductal adenocarcinoma.

Keywords: eIF3a; Proliferation; Migration; Invasion; Pancreatic Ductal Adenocarcinoma
pancreatic cancer cells. The tumorigenic abilities of pancreatic cancer cell lines were also examined after eIF3a knockdown in a nude mouse model. This report represented the first study as far as we know to investigate the role of eIF3a in the cell proliferation and metastasis in pancreatic cancer.

MATERIALS AND METHODS

Cell culture
PANC-1, AsPC-1, SW1990, Capan-1, Miapaca-2, BxPC-3, and L3.6pL cells were purchased from Shanghai Institutes for Biological Sciences (Shanghai, China). Miapaca-2 cells were maintained in RPMI 1640 medium (Gibco, MD, USA). PANC-1, AsPC-1, SW1990, Capan-1, BxPC-3, and L3.6pL were maintained in Dulbecco’s modified Eagle medium (DMEM) (Gibco). All media were supplemented with 10% fetal bovine serum (Gibco), and the cells were cultured in 5% CO2 at 37°C.

Patients and tissue samples
Slides from 140 clinical patients suffering from pancreatic ductal adenocarcinoma were collected (5 slides for each case). Clinicopathological information of these patients were also obtained from the First Affiliated Hospital, Zhejiang University. Another 30 patients who underwent surgery at the First Affiliated Hospital, Zhejiang University from 2010 to 2015 were chosen after histological verification of pancreatic ductal adenocarcinoma. For these 30 patients, fresh cancerous tissues and the paired adjacent non-cancerous tissues were synchronously collected for each patient. None of the 30 patients received preoperative chemotherapy or radiotherapy.

Immunohistochemical analysis and evaluation of eIF3a expression
Immunohistochemical staining was performed using a standard immunoperoxidase staining procedure, and the eIF3a expression in benign and malignant specimens was evaluated as follows: immunoreaction extent, 0 score (positive cells in less than 5% of total); 1 score (positive cells with 5%-25%); 2 scores (positive cells with 25%-50%); and 3 scores (positive cells with greater than 50%); staining intensity, 0 score (no coloration); 1 score (pale yellow); 2 scores (yellow); and 3 scores (claybank). The two scores were then multiplied: 0 score as negative; 1-3 scores as weak; 4-6 scores as moderate; > 6 scores as strong.

RNA isolation and semi-quantitative reverse transcription-PCR
RNAs were isolated from the 30 cases of pancreatic ductal adenocarcinoma. Total RNAs from PANC-1, AsPC-1, SW1990, Capan-1, Miapaca-2, BxPC-3 and L3.6pL cells were extracted using TRIzol solution (Invitrogen, Carlsbad, CA, USA). The primers for eIF3a and β-actin were listed as follows: eIF3a: 5’-ACAG-GCAGTGTGTGAC-3’ (forward) and 5’-GAGATAGCCCCGT-GAATA-3’ (reverse); β-actin: 5’-TGGCACCCAGCAATGGA-3’ (forward) and 5’-CTAAGTCATAGCCCGCCTAGAAGCA-3’ (reverse). The PCR was performed as previously described (18). The house-keeping gene β-actin was included as an internal standard.

Western blot analysis
Cells were collected and solubilized with Cell Lysis/Extraction Reagent (Sigma) and with complete protein inhibitor cocktail (Roche, IN, USA). The equal amount of sample was loaded in each well of a 12% gel and subjected to SDS-PAGE. Gels were transferred to polyvinylidene difluoride (PVDF) membrane (Millipore, MA, USA). The membrane was then incubated with primary antibodies against eIF3a (1:1,000) and β-actin (1:2,000) for 4°C overnight. Both antibodies were purchased from Santa Cruz Co. (Santa Cruz, CA, USA). After washing with TBS-T, the membrane was incubated with secondary antibody, and the signals were visualized using the enhanced chemiluminescent detection reagent from Pierce (Rockford, IL, USA).

Lentivirus-mediated RNA interference of eIF3a
The small hairpin RNA (shRNA)-encoding oligonucleotides for eIF3a (5´-gatcccccccttgccagttattgagtaattcaagagattactcaatacctgaaggttggtaa-3´) (20), which was targeting the 3’UTR, were synthesized by Sangon (Shanghai, China). The package of lentivirus was as previously described (18).

Cell viability detection
The cell viability of SW1990 and Capan-1 cells with or without eIF3a depletion were assessed using a cell counting kit-8 (CCK-8) assay (Beyotime, Nantong, China) based on the manufacturer’s instructions. Briefly, cells transfected with (shRNA group) or without specific shRNA against eIF3a (negative control group, NC group) were seeded into 96-well plates at an initial concentration of 6,000 cells per well. Cells were incubated for a total of 7 days. On each monitored day, 10 μL of CCK-8 solution was added to each well and cells were further incubated at 37°C for 2 hours, the absorbance was measured by an ELISA reader at a wave length of 450 nm.

Colony formation assay
Anchorage-independent growth was also assessed by colony formation ability. A total of 1,000 cells were seeded in 6 cm-well plates and cultured at 37°C. The culture medium was changed at regular intervals after 10-15 days according to the character of each cell line. The adherent cells were washed with PBS twice, fixed with 4% paraformaldehyde, and stained with 0.1% crystal violet (Sigma-Aldrich, NY, USA). The total number of colonies (≥ 50 cells/colony) was counted, and the results were expressed as the average of three independent experiments.
**Wound-healing assay**
Pancreatic cancer cells SW1990 and Capan-1 were seeded into 6-well plates and infected with either control or specific shRNAs. Forty-eight hours post-transfection, cells were washed with pre-warmed PBS and then 10 μL sterile pipette tips were used to scrape a straight line in the center of each group. After scratch, cells were rinsed again with PBS for three times and incubated with serum-free medium immediately. In 37°C incubator, cells were allowed to grow for additional 24 hours when scratches were observed and photographed. Images were captured using a Nikon microscope at a magnification of 200 ×. Each assay was repeated at least three times in triplicate.

**Transwell assay**
SW1990 and Capan-1 cells were cultured in 24-well plates and infected with specific eIF3a shRNA. After 48 hours, cells were harvested with serum-free DMEM media and 150 μL of cell suspension (approximate 3 × 10⁶ cells) was placed in the upper chamber (Corning, New York, NY, USA). Meanwhile, the lower chamber was added with 600 μL DMEM medium supplied with 10% FBS. As for the invasion assay, the chamber was pre-coated with Matrigel (Corning, NY, USA) for 6 hours before seeding cells. After incubated for additional 12 hours, cells were fixed with pre-cold methanol for 10 minutes and then stained with crystal violet (0.1%) for 5 minutes. Afterwards, the images were captured under a microscope (Nikon).

**Mouse xenografts**
Female Balb/c nude mice (6-8 weeks of age, weighing 18-20 g) were obtained from Shanghai Laboratory Animal Center (Shanghai, China). The mice were housed in micro-isolator cages with autoclaved bedding in a specific pathogen-free facility with 12-hour light/dark cycles. The mice were divided into two groups (NC group and shRNA-injected group, n = 5 for each group). According to body weight before the experiment, 2 × 10⁶/site cell was subcutaneously injected into the right flanks of the nude mice. Tumor growth was monitored every 3-4 days and was measured in two dimensions. The tumor volume was calculated using the following formula: tumor volume = width² (mm²) × length (mm)/2, where width and length were the shortest and longest diameters, respectively. After four weeks, the mice were sacrificed, and the primary tumors were dissected and measured. All animal experiments were performed in compliance with the Ethics Committee guidelines of the first affiliated hospital, Zhejiang University.

**Statistical analysis**
Statistical analysis was conducted using SPSS software version 18.0 (SPSS Inc., Chicago, IL, USA). The Pearson χ² test was used to analyze eIF3a expression in pancreatic cancer and normal pancreatic tissue. The results were presented as the mean ± standard deviation (SD) of three independent experiments. A P value of < 0.05 was considered significant.

**Ethics statement**
This study was approved by the institutional review board of The First Affiliated Hospital, Zhejiang University. All of the patients provided informed consents.

**RESULTS**

**Aberrant eIF3a expression in human pancreatic cancer tissues and the eIF3a expression correlated with tumor metastasis and tumor staging**
To investigate eIF3a expression level in human pancreatic tissues, qRT-PCR and immunohistochemistry staining assays were performed to detect eIF3a in both normal and pancreatic cancerous tissues. As revealed in Fig. 1A, in the obtained 30 tissues, the relative mRNA level of eIF3a in human pancreatic ductal carcinoma tissues was elevated by seven-fold as compared with that of normal counterpart (P < 0.001). Furthermore, in the slides from 140 cases of pancreatic ductal carcinoma, IHC staining showed that eIF3a was abundantly detected in malignant ductal adenocarcinoma patients, but not in normal pancreatic duct epithelial tissues (Fig. 1B). Overall, aberrant eIF3a expression in malignant lesions of the pancreas was observed. The aberrant eIF3a expression was then statistically analyzed with the clinico-pathological variables (Table 1). It was revealed that the expression of eIF3a was not significantly correlated with variables such as age of onset, gender, tumor size, location and differentiation (P = 0.159, 1.00, 0.101, and 0.541, respectively). However, statistical correlation of eIF3a expression with nodal metastasis and TNM stage were observed (P = 0.017 for metastasis, and P = 0.003 for TNM stage). These observations suggested that the overexpression of eIF3a was associated with the aggressiveness in pancreatic ductal adenocarcinoma.

**Constitutive eIF3a expression in human pancreatic cancer cell lines and knockdown of its expression in vitro**
The high eIF3a expression level in malignant pancreatic lesions prompted eIF3a expression assessment in pancreatic cancer cell lines. In all the seven cell lines that were examined, Western blot analysis detected eIF3a protein levels (Fig. 2A). SW1990 and Capan-1 cells displayed the highest eIF3a protein level, whereas MiaPaCa-2 cells had the lowest eIF3a expression level. Therefore, SW1990 and Capan-1 cell lines were chosen for the subsequent analyses. Specific shRNA against eIF3a was stably transfected into SW1990 and Capan-1 cells to explore the detailed role of eIF3a in tumorigenicity. The efficiency of eIF3a knockdown was confirmed through Western blot analysis where the protein level of eIF3a was barely detected after transfection of the specific shRNA into SW1990 and Capan-1 cells (Fig. 2B).
These data suggested the high specificity and transfection efficacy of eIF3a shRNA.

**Knockdown of eIF3a inhibited cell proliferation and colony formation in pancreatic cancer cells**

Next, CCK-8 assay and colony formation assay were performed to explore the detailed role of eIF3a in pancreatic cancer cells. In cell proliferation assay, significant disparities were observed from the fourth day in SW1990 cells and the fifth day in Capan-1 cells (Fig. 3A). The inhibitory effects grew as the time extended in both cells. As for the colony formation assay, it was shown that knockdown of eIF3a caused visual decreases of colonies in both cell lines (Fig. 3B). By counting the colonies numbers, it was further shown that more than 60% of SW1990 colonies and 75% of Capan-1 colonies were suppressed upon eIF3a shRNA transfection (Fig. 3C). These results indicated that knockdown of eIF3a retarded cell proliferation and colony formation in pancreatic cancer cells.
Knockdown of eIF3a inhibited wound recovery abilities in pancreatic cancer cells

Wound-healing process reflects the cell migration abilities after initial scratches. To assess the wound recovery abilities, both SW1990 cells and Capan-1 cells were subject to wound-healing assays. Twenty-four hours after scratch, it was observed that the wound was mostly closed in the control SW1990 and Capan-1 cells. However, eIF3a-depleted cells barely recovered the initial scratches (Fig. 4, upper panels). Consistently, as compared with the control cells, eIF3a-depleted SW1990 and Capan-1 cells exhibited only approximately 50% migration abilities as reflected by the recovered wound areas (Fig. 4, lower panels). These observations suggested that eIF3a was associated with cell migration abilities in both SW1990 and Capan-1 cells.

Knockdown of eIF3a decreased cell migration and invasion abilities in human pancreatic cancer cell lines

Moreover, knockdown of eIF3a with specific shRNA inhibited cell migration and invasion based on observations from transwell assays (Fig. 5). The migration rate was inhibited by 55% for SW1990 cells and 46% for Capan-1 cells. Meanwhile, cell invasion rate was decreased by more than 60% for both cell lines. All of these data jointly suggested that eIF3a could promote cell metastasis in human pancreatic cancer.

Knockdown of eIF3a inhibited the tumorigenic ability in a xenotransplanted model

Two pancreatic cancer cell groups (NC and shRNA against eIF3a) were subcutaneously implanted into the nude mice to determine the impact of eIF3a depletion on pancreatic tumor
Wang S-Q, et al. • eIF3a for Cell Proliferation in Pancreatic Cancer

• eIF3a for Cell Proliferation in Pancreatic Cancer

http://jkms.org
1591
http://dx.doi.org/10.3346/jkms.2016.31.10.1586

Figure 4. Knockdown of eIF3a inhibited the wound recovery in SW1990 cells and Capan-1 cells. Both SW1990 cells and Capan-1 cells were subject to wound-healing assays after transfection with scramble or specific shRNA against eIF3a. Twenty-four hours after the scratch, wound recovery rates were photographed and the recovered areas which represented cell migration were quantified and averaged from three independent assays.

*P < 0.01.

Fig. 4. Knockdown of eIF3a inhibited the wound recovery in SW1990 cells and Capan-1 cells. Both SW1990 cells and Capan-1 cells were subject to wound-healing assays after transfection with scramble or specific shRNA against eIF3a. Twenty-four hours after the scratch, wound recovery rates were photographed and the recovered areas which represented cell migration were quantified and averaged from three independent assays.

*P < 0.01.

growth in vivo. As shown in Fig. 6A and 6B, the tumor volume of eIF3a-depleted xenografts was significantly decreased compared with that of tumors formed by scramble shRNA-transfected cells. After four weeks, mice were sacrificed and tumors were all dissected and weighed. The tumors were generally lighter when eIF3a was knocked down in experimental mice (Fig. 6C). These data indicated that eIF3a displayed a potential tumorigenic ability in vivo.

DISCUSSION

Pancreatic cancer still remains a serious health problem, with a 5-year survival rate for all stages at < 5% (1). Most patients were diagnosed at an advanced stage with poor prognosis. Novel molecules crucially involved in pancreatic cancer cell growth are urgently needed for early detection and intervention.

As the largest and most complex subunit of eIF3, eIF3a has been identified in a wide range of eukaryotic organisms, including fungi (21), yeast (22), insects (23), plants (24) and mammals (25). Due to its important regulatory effects in protein translation initiation, it is involved in various cancers, including lung cancer (26) and tumors of stomach (27), urinary bladder (28), colon (29) and ovarian (30). However, the detailed role of eIF3a in human pancreatic cancer remains to be uncovered.

The present study showed that eIF3a was abundantly detected in pancreatic cancer cell lines and malignant ductal adenocarcinoma tissues, but not in normal pancreatic duct epithelial tissues, suggesting the exclusively high expression of eIF3a in cancerous tissues. Initially, the overexpression of eIF3a was observed in breast cancer (31). Later on, the overexpression of eIF3a was also widely reported in other human tumors. Our data together with previous reports collectively suggest the prevalence of eIF3a overexpression in the development of cancers.

Moreover, knockdown of eIF3a in pancreatic cancer cells inhibited cell proliferation and metastasis. While control cells proliferated normally in the culture medium, eIF3a-depleted SW1990 and Capan-1 cells were significantly inhibited from cell proliferation and clonogenisis. Consistently, the pancreatic cancer cell growth rates were also impaired in xenotransplanted mice. Moreover, wound-healing assay showed that depletion of eIF3a significantly slowed down the wound recovery processes in SW1990 and Capan-1 cells. Transwell migration and invasion assays further showed that cell migration and invasion abilities were significantly inhibited by knockdown of eIF3a in SW1990 and Capan-1 cells. All these data strongly suggest that eIF3a is critical for cell proliferation and metastasis in pancreatic cancer.

In addition, we observed the association between eIF3a expression and common clinicopathological variables. The expression of eIF3a in clinical pancreatic cancer tissues were significantly correlated with tumor TNM stage (P = 0.003) and nodal metastasis (P = 0.017). Previously, eIF3a was observed to be associated with patients’ survival in ovarian cancer (19). In
non-small cell lung cancer, altered eIF3a predicted the prognosis of this malignancy (26). These clinical studies indicated that the aberrant expression of eIF3a in human cancers might serve as a prognostic factor that could be detected in clinic.

Of particular interest to us, despite wide reports on eIF3a, the pathways that contribute to eIF3a-mediated biological activi-
ties remain largely unrevealed. Interestingly, as a translation initiator, eIF3a could affect cancer phenotype independent of translation initiation (20), indicating that translation initiation is not the only pathway that underlies eIF3a function in human cancers. On the contrary, eIF3a is more possible to suppress cellular protection against DNA damages via inhibiting DNA repair, leading to higher frequency of gene mutation for tumorigenesis and lower sensitivity of cancer cells to DNA-damaging-associated anticancer drugs (15,16). Hence, eIF3a may function to control DNA repair machinery in the development of human cancers which may be independent of translation initiation. However, more work needs to be done.

In all, the present study identified eIF3a as a critical mediator of cell proliferation, migration and invasion in pancreatic cancer. Knockdown of eIF3a by specific shRNA significantly inhibited cell proliferation and clonogenic abilities in vitro and tumor growth in vivo. High expression of eIF3a correlated with tumor aggressiveness and was closely associated with cancerous cell migration and invasion abilities in pancreatic cancer. Therefore, eIF3a may be a novel target molecule in drug development for pancreatic cancer treatment and prevention. Molecular therapies against eIF3a might be a novel strategy as for the early diagnosis and treatment of pancreatic cancer.

DISCLOSURE

The authors have no potential conflicts of interest to disclose.

AUTHOR CONTRIBUTION

Conception and coordination of the study: Wang SQ. Design of ethical issues: Wang SQ, Liu Y, Yao MY, Jin J. Acquisition of data: Wang SQ, Liu Y. Data review: Yao MY. Statistical analysis: Wang SQ. Manuscript preparation: Wang SQ, Liu Y, Yao MY, Jin J. Manuscript approval: all authors.

ORCID

Shu-qian Wang http://orcid.org/0000-0002-6909-1516
Yu-Liu http://orcid.org/0000-0002-6813-2689
Min-ya Yao http://orcid.org/0000-0003-2206-8631
Jing Jin http://orcid.org/0000-0001-6737-964X

REFERENCES

1. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet 2004; 363: 1049-57.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015; 65: 5-29.
3. Van Cutsen E, Aerts R, Haustermans K, Topal B, Van Steenbergen W, Verslype C. Systemic treatment of pancreatic cancer. Eur J Gastroenterol Hepatol 2004; 16: 265-74.
4. Li YY, Popivanova BK, Nagai Y, Ishikura H, Fujii C, Mukaida N. Pim-3, a proto-oncogene with serine/threonine kinase activity, is aberrantly expressed in human pancreatic cancer and phosphorylates bad to block bad-mediated apoptosis in human pancreatic cancer cell lines. Cancer Res 2006; 66: 6741-7.
5. Maitra U, Stringer EA, Chaudhuri A. Initiation factors in protein biosynthesis. Annu Rev Biochem 1982; 51: 869-900.
6. Dong Z, Zhang JT. Initiation factor eIF3 and regulation of mRNA translation, cell growth, and cancer. Crit Rev Oncol Hematol 2006; 59: 169-80.
7. Yin JY, Dong Z, Liu ZQ, Zhang JT. Translational control gone awry: a new mechanism of tumorigenesis and novel targets of cancer treatments. Biosci Rep 2011; 31: 1-15.
8. Unbehaun A, Borukhov SI, Hellen CU, Pestova TV. Release of initiation factors from 48S complexes during ribosomal subunit joining and the link between establishment of codon-anticodon base-pairing and hydrolysis of eIF2-bound GTP. Genes Dev 2004; 18: 3078-93.
9. Asano K, Vornlocher HP, Richter-Cook NJ, Merrick WC, Hinnebusch AG, Hershey JW. Structure of cDNAs encoding human eukaryotic initiation factor 3 subunits. Possible roles in RNA binding and macromolecular assembly. J Biol Chem 1997; 272: 27042-52.
10. Zhou C, Arslan F, Wee S, Krishnan S, Ivanov AR, Oliva A, Leatherwood J, Wolf DA. PCI proteins eIF3e and eIF3m define distinct translation initiation factor 3 complexes. BMC Biol 2005; 3: 14.
11. Saletta F, Suryo Rahmanto Y, Richardson DR. The translational regulator eIF3a: the tricky eIF3 subunit. Biochim Biophys Acta 2010; 1806: 275-86.
12. Zhang L, Pan X, Hershey JW. Individual overexpression of five subunits of human translation initiation factor eIF3 promotes malignant transformation of immortal fibroblast cells. J Biol Chem 2007; 282: 5790-800.
13. Dong Z, Liu Y, Zhang JT. Regulation of ribonucleotide reductase M2 expression by the upstream AUGs. Nucleic Acids Res 2005; 33: 2715-25.
14. Smith MD, Gu Y, Querol-Audí J, Vogan JM, Núñez A, Cate JH. Human-like eukaryotic translation initiation factor 3 from Neurospora crassa. PLoS One 2013; 8: e78715.
15. Aylett CH, Boehringer D, Erzberger JP, Schafer T, Ban N. Structure of a yeast 40S-eIF1-eIF1A-eIF3-eIF3j initiation complex. Nat Struct Mol Biol 2015; 22: 269-71.
16. LeFebvre AK, Korneeva NL, Trutschl M, Cvek U, Duzan RD, Bradley CA, Hershey JW, Rhoads BE. Translation initiation factor eIF4G-1 binds to eIF3 through the eIF3e subunit. J Biol Chem 2006; 281: 22917-32.
17. Dong Z, Arnold RJ, Yang Y, Park MH, Hrinicova P, Mechref Y, Novotny MV, Zhang JT. Modulation of differentiation-related gene 1 expression by cell cycle blocker mimosine, revealed by proteomic analysis. Mol Cell Proteomics 2005; 4: 993-1001.
18. He J, Shi J, Fu X, Mao L, Zhou T, Qiu Y, Zhu B. The clinicopathologic and prognostic significance of gross classification on solitary hepatocellular carcinoma after heptectomy. Medicine (Baltimore) 2015; 94: e1331.
19. Shen J, Yin JY, Li XP, Liu ZQ, Wang Y, Chen J, Qu J, Xu XJ, McLeod HL, He YJ, et al. The prognostic value of altered eIF3a and its association with p27 in non-small cell lung cancers. PLoS One 2014; 9: e96008.
20. Chen G, Burger MM. p150 overexpression in gastric carcinoma: the association with p53, apoptosis and cell proliferation. Int J Cancer 2004; 112: 393-8.
21. Chen G, Burger MM. p150 expression and its prognostic value in squamous-cell carcinoma of the esophagus. Int J Cancer 1999; 84: 95-100.
22. Haybaeck J, O’Connor T, Spilka R, Spizzo G, Ensinger C, Mikuz G, Brunhuber T, Vogtsseder A, Theurl I, Salvenmoser W, et al. Overexpression of p150, a part of the large subunit of the eukaryotic translation initiation factor 3, in colon cancer. *Anticancer Res* 2010; 30: 1047-55.

23. Spilka R, Laimer K, Bachmann F, Spizzo G, Vogtsseder A, Wieser M, Müller H, Haybaeck J, Obrist P. Overexpression of eIF3a in squamous cell carcinoma of the oral cavity and its putative relation to chemotherapy response. *J Oncol* 2012; 2012: 901956.

24. Bachmann F, Bänziger R, Burger MM. Cloning of a novel protein overexpressed in human mammary carcinoma. *Cancer Res* 1997; 57: 988-94.

25. Wu YH, Li XW, Li WQ, Li XH, Li YJ, Hu GY, Liu ZQ, Li D. Fluorofenidone attenuates bleomycin-induced pulmonary fibrosis by inhibiting eukaryotic translation initiation factor 3a (eIF3a) in rats. *Eur J Pharmacol* 2016; 773: 42-50.

26. Yin JY, Shen J, Dong ZZ, Huang Q, Zhong MZ, Feng DY, Zhou HH, Zhang JT, Liu ZQ. Effect of eIF3a on response of lung cancer patients to platinum-based chemotherapy by regulating DNA repair. *Clin Cancer Res* 2011; 17: 4600-9.

27. Liu K, Lei Z, Yao H, Lei S, Zhao H. Impact of a Eukaryotic Translation Initiation Factor 3a Polymorphism on Susceptibility to Gastric Cancer. *Med Princ Pract* 2016; DOI: 10.1159/000447741

28. Spilka R, Ernst C, Bergler H, Rainer J, Flechsig S, Vogtsseder A, Lederer F, Benesch M, Brunner A, Geley S, Eger A, et al. eIF3a is over-expressed in urinary bladder cancer and influences its phenotype independent of translation initiation. *Cell Oncol* 2014; 37: 253-67.

29. Liu Z, Dong Z, Yang Z, Chen Q, Pan Y, Yang Y, Cai P, Zhang X, Zhang JT. Role of eIF3a (eIF3 p170) in intestinal cell differentiation and its association with early development. *Differentiation* 2007; 75:652-61.

30. Zhang Y, Yu JJ, Tian Y, Li ZZ, Zhang CY, Zhang SF, Cao LQ, Zhang Y, Qian CY, Zhang W. eIF3a improve cisplatin sensitivity in ovarian cancer by regulating XPC and p27Kip1 translation. *Oncotarget* 2015; 6:25441-51.

31. Olson JE, Wang X, Goode EL, Pankratz VS, Fredericksen ZS, Vierkant RA, Pharoah PD, Cerhan JR, Couch FJ. Variation in genes required for normal mitosis and risk of breast cancer. *Breast Cancer Res Treat* 2010; 119: 421-30.